<DOC>
	<DOCNO>NCT00004171</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Phase II trial study effectiveness chemotherapy follow peripheral stem cell transplantation treat patient Hodgkin 's disease non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Peripheral Stem Cell Transplantation Following Radiation Therapy Treating Patients With Hodgkin 's Disease Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicity response intensive chemotherapy follow autologous peripheral blood stem cell transplantation patient Hodgkin 's disease non-Hodgkin 's lymphoma receive prior chemotherapy and/or radiotherapy . OUTLINE : Patients receive oral busulfan every 6 hour day -9 -6 cyclophosphamide IV 2 hour day -5 -2 . Autologous peripheral blood stem cell reinfused day 0 . Patients follow monthly 1 year . PROJECTED ACCRUAL : Not specify</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove Hodgkin 's disease OR Histologically proven nonHodgkin 's lymphoma ( NHL ) Intermediate grade OR Large cell immunoblastic ( high grade ) Refractory standard therapy relapse follow initial complete remission Must receive radiotherapy extent longer eligible involved field radiation , cyclophosphamide , total body irradiation No CNS disease A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : Physiologic 65 Performance status : ECOG 02 Life expectancy : At least 2 month Hematopoietic : Not specify Hepatic : Not specify Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance great 50 mL/min Cardiovascular : No active heart disease No congestive heart failure No myocardial infarction last 3 month No significant arrhythmia require medication Pulmonary : No significant nonneoplastic pulmonary disease No chronic obstructive pulmonary disease Diffusing capacity least 50 % predict OR FEV1 and/or FVC least 75 % predict ( unless due NHL Hodgkin 's disease ) Other : HIV negative No clinical evidence AIDS PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>childhood immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
</DOC>